Apolipoprotein M Inhibits Angiogenic and Inflammatory Response by Sphingosine 1-Phosphate on Retinal Pigment Epithelium Cells
Open Access
- 31 December 2017
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (1) , 112
Abstract
Sphingosine 1-phosphate (S1P) is a potent lipid mediator that modulates inflammatory responses and proangiogenic factors. It has been suggested that S1P upregulates choroidal neovascularization (CNV) and may be deeply involved in the pathogenesis of exudative age-related macular degeneration (AMD). Recent studies have suggested that apolipoprotein M (ApoM), a carrier protein for S1P, modulates the biological properties of S1P in the pathogenesis of atherosclerosis. However, the role of ApoM/S1P in AMD has not been explored. We investigated the effect of S1P on proangiogenic factors in human retinal pigment epithelium (RPE) cell lines in vitro. S1P promoted the expression of vascular endothelial growth factor in RPE cells. Hypoxia inducible factor-1α expression was also upregulated. These S1P-induced enhancements in growth factors and chemotactic cytokines in RPE cells were significantly inhibited by ApoM treatment. Additionally, in vivo experiments using a laser-induced CNV murine model demonstrated that intravitreal ApoM injection significantly reduced the progression of CNV formation. Although the detailed mechanisms remain to be elucidated, the present results provide a novel potential therapeutic target for AMD, and demonstrate a suppressive role for ApoM and S1P in the pathology of CNV progression.Keywords
This publication has 61 references indexed in Scilit:
- Sphingosine-1-Phosphate as a Regulator of Hypoxia-Induced Factor-1α in Thyroid Follicular Carcinoma CellsPLOS ONE, 2013
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein MProceedings of the National Academy of Sciences, 2011
- Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of PrematurityNew England Journal of Medicine, 2011
- Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)Diabetes Care, 2010
- Blockade of sphingosine‐1‐phosphate reduces macrophage influx and retinal and choroidal neovascularizationJournal of Cellular Physiology, 2008
- “Inside-Out” Signaling of Sphingosine-1-Phosphate: Therapeutic TargetsPharmacological Reviews, 2008
- Essential role of sphingosine 1–phosphate receptor 2 in pathological angiogenesis of the mouse retinaJournal of Clinical Investigation, 2007
- Pharmacologic Manipulation of Sphingosine Kinase in Retinal Endothelial Cells: Implications for Angiogenic Ocular DiseasesInvestigative Ophthalmology & Visual Science, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006